UnitedHealth excludes Lantus, Neupogen from 2017 drug list

UnitedHealth Group Inc. (NYSE:UNH) will remove Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY) and Neupogen filgrastim from Amgen Inc. (NASDAQ:AMGN) from its 2017 Prescription Drug List, substituting follow-on biologic Basaglar insulin glargine and biosimilar Zarxio filgrastim-sndz. The change will be effective on Jan. 1, 2017, for Neupogen, and on April 1, 2017, for Lantus.

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) markets Zarxio, and Eli Lilly and Co. (NYSE:LLY) markets Basaglar. ...